clinical trial · NCT05827835
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Zhejiang University·phase2·recruiting·n = 30
Hematologic DiseasesNeoplasmsCD7 CAR-T cells injectionAllogeneic hematopoietic stem cell transplantation
brief summary
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases
started
Apr 30, 2023
primary completion
Apr 25, 2026
completion
Apr 25, 2027
last updated
Aug 13, 2025
official title
A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol